• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dose-limiting hypotension with the 5-HT3-antagonist batanopride (BMY-25801).

作者信息

Herrstedt J, Jeppesen B H, Dombernowsky P

机构信息

Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.

出版信息

Ann Oncol. 1991 Feb;2(2):154-5. doi: 10.1093/oxfordjournals.annonc.a057882.

DOI:10.1093/oxfordjournals.annonc.a057882
PMID:2054319
Abstract
摘要

相似文献

1
Dose-limiting hypotension with the 5-HT3-antagonist batanopride (BMY-25801).5-羟色胺3拮抗剂巴坦必利（BMY-25801）的剂量限制性低血压
Ann Oncol. 1991 Feb;2(2):154-5. doi: 10.1093/oxfordjournals.annonc.a057882.
2
A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.一项随机、双盲研究，比较接受中度致吐性化疗的患者中六种剂量的巴他必利（BMY-25801）与甲泼尼龙的疗效。
Ann Oncol. 1991 Oct;2(9):681-6. doi: 10.1093/oxfordjournals.annonc.a058049.
3
Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis.甲氧氯普胺和巴氯必利预防顺铂所致呕吐的双盲随机交叉研究
Cancer Chemother Pharmacol. 1991;28(3):226-7. doi: 10.1007/BF00685516.
4
Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis.巴他必利（BMY-25801）：一种用于预防癌症化疗引起呕吐的新型5-羟色胺3受体拮抗剂。
Cancer Treat Rev. 1990 Sep;17(2-3):319-27. doi: 10.1016/0305-7372(90)90064-m.
5
BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.BMY - 25801，一种不具有D2 - 多巴胺受体拮抗剂特性的止吐药。
J Pharmacol Exp Ther. 1988 Mar;244(3):830-7.
6
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.昂丹司琼与甲氧氯普胺预防环磷酰胺、氟尿嘧啶和多柔比星或表柔比星化疗所致呕吐的随机双盲对照研究。
J Clin Oncol. 1990 Jun;8(6):1063-9. doi: 10.1200/JCO.1990.8.6.1063.
7
[Domperidone: an alternative to orthopramides in the case of adverse reactions in the central nervous system].
Med Clin (Barc). 1996 Sep 14;107(8):317-8.
8
Comparative central nervous system effects and pharmacokinetics of neu-metoclopramide and metoclopramide in healthy volunteers.健康志愿者中神经-甲氧氯普胺与甲氧氯普胺的中枢神经系统效应及药代动力学比较
J Clin Pharmacol. 1997 Mar;37(3):222-8. doi: 10.1002/j.1552-4604.1997.tb04784.x.
9
A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.静脉注射甲磺酸多拉司琼与甲氧氯普胺预防接受大剂量顺铂化疗的癌症患者恶心和呕吐的双盲、多中心比较。
Support Care Cancer. 1997 Jan;5(1):22-30. doi: 10.1007/BF01681958.
10
Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial.甲氧氯普胺联合地塞米松预防术后恶心呕吐：随机双盲多中心试验
BMJ. 2006 Aug 12;333(7563):324. doi: 10.1136/bmj.38903.419549.80. Epub 2006 Jul 21.

引用本文的文献

1
The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment.巴他必利及其代谢产物在肾功能不全受试者中的处置和蛋白结合情况。
Eur J Clin Pharmacol. 1993;45(1):59-63. doi: 10.1007/BF00315351.
2
Future of the management of emesis.
Support Care Cancer. 1994 Sep;2(5):301-3. doi: 10.1007/BF00365582.
3
5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.5-羟色胺3受体拮抗剂。其在癌症治疗引起的呕吐方面的现状及未来潜力概述
Drugs. 1991 Oct;42(4):551-68. doi: 10.2165/00003495-199142040-00002.